Cancer predisposing syndromes in childhood and adolescence pose several challenges necessitating interdisciplinary care in dedicated programs.
cancer
children
hereditary
predisposition
preventive testing
surveillance
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2024
2024
Historique:
received:
31
03
2024
accepted:
20
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
epublish
Résumé
Genetic disposition is a major etiologic factor in childhood cancer. More than 100 cancer predisposing syndromes (CPS) are known. Surveillance protocols seek to mitigate morbidity and mortality. To implement recommendations in patient care and to ascertain that the constant gain of knowledge forces its way into practice specific pediatric CPS programs were established. We retrospectively analyzed data on children, adolescents, and young adults referred to our pediatric CPS program between October 1, 2021, and March 31, 2023. Follow-up ended on December 31, 2023. We identified 67 patients (30 male, 36 female, 1 non-binary, median age 9.5 years). Thirty-five patients were referred for CPS surveillance, 32 for features suspicious of a CPS including café-au-lait macules ( The diverse pediatric CPSs pose several challenges necessitating interdisciplinary care in specified CPS programs. To ultimately improve outcome including psychosocial well-being joint clinical and research efforts are necessary.
Identifiants
pubmed: 38887560
doi: 10.3389/fped.2024.1410061
pmc: PMC11180882
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1410061Informations de copyright
© 2024 Kaffai, Angelova-Toshkin, Weins, Ickinger, Steinke-Lange, Vollert, Frühwald and Kuhlen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Nurs Stud. 2013 Jun;50(6):870-80
pubmed: 23026156
J Clin Endocrinol Metab. 2015 Feb;100(2):E214-22
pubmed: 25459911
AMA J Ethics. 2022 Jul 1;24(7):E685-693
pubmed: 35838399
Clin Cancer Res. 2017 Jun 1;23(11):e1-e5
pubmed: 28572261
Fam Cancer. 2021 Oct;20(4):305-316
pubmed: 33532948
Clin Cancer Res. 2023 Apr 3;29(7):1243-1251
pubmed: 36693186
Cancers (Basel). 2023 Feb 22;15(5):
pubmed: 36900174
Lancet Oncol. 2023 Oct;24(10):1147-1156
pubmed: 37797633
Clin Cancer Res. 2017 Jun 15;23(12):e62-e67
pubmed: 28620006
Clin Cancer Res. 2018 Apr 1;24(7):1594-1603
pubmed: 29351919
J Clin Oncol. 2022 Jun 10;40(17):1892-1902
pubmed: 35230882
Eur J Pediatr. 2022 Apr;181(4):1585-1596
pubmed: 34950979
Mol Cell Pediatr. 2022 Feb 21;9(1):3
pubmed: 35187600
Clin Cancer Res. 2017 Jun 1;23(11):e6-e13
pubmed: 28572262
J Health Monit. 2023 Dec 13;8(4):17-23
pubmed: 38384741
Eur J Hum Genet. 2020 Nov;28(11):1481-1482
pubmed: 32814850
Clin Cancer Res. 2017 Jul 1;23(13):e107-e114
pubmed: 28674119
J Med Genet. 2019 Feb;56(2):53-62
pubmed: 30415209
Clin Cancer Res. 2017 Nov 1;23(21):e133-e137
pubmed: 29093018
J Med Genet. 2023 Jul;60(7):679-684
pubmed: 36411031
Clin Chem Lab Med. 2020 Oct 01;59(2):353-363
pubmed: 33001846
Pediatr Blood Cancer. 2019 Jan;66(1):e27445
pubmed: 30207072
Fam Cancer. 2010 Mar;9(1):27-35
pubmed: 19760114
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
Clin Cancer Res. 2017 Jul 1;23(13):e123-e132
pubmed: 28674121
Pediatr Blood Cancer. 2020 Feb;67(2):e28056
pubmed: 31724322
Clin Cancer Res. 2017 Jul 1;23(13):e98-e106
pubmed: 28674118
J Clin Oncol. 2010 Jun 20;28(18):3008-14
pubmed: 20479422
Eur J Hum Genet. 2021 Aug;29(8):1301-1311
pubmed: 33840814
Pediatr Blood Cancer. 2017 Aug;64(8):
pubmed: 28097779
Cancer. 2024 Feb 1;130(3):467-475
pubmed: 37788149
Nat Rev Endocrinol. 2019 May;15(5):299-311
pubmed: 30842651
Clin Cancer Res. 2017 Jun 15;23(12):e68-e75
pubmed: 28620007
J Neurooncol. 2010 Nov;100(2):199-207
pubmed: 20352473
Clin Cancer Res. 2017 Jun 1;23(11):e32-e37
pubmed: 28572265
Clin Cancer Res. 2017 Jun 1;23(11):e38-e45
pubmed: 28572266
Pediatr Blood Cancer. 2021 Aug;68(8):e29021
pubmed: 33788392
J Genet Couns. 2024 Feb 13;:
pubmed: 38348940
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Fam Cancer. 2010 Dec;9(4):647-54
pubmed: 20658357
Pediatr Blood Cancer. 2019 Nov;66(11):e27916
pubmed: 31342632
Clin Genet. 2010 May;77(5):483-91
pubmed: 20184621
PLoS Genet. 2020 Dec 17;16(12):e1009231
pubmed: 33332384
Genet Med. 2021 Aug;23(8):1506-1513
pubmed: 34012067
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29507082
Clin Cancer Res. 2017 Jun 1;23(11):e14-e22
pubmed: 28572263
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
Pediatrics. 1993 Jun;91(6):1116-20
pubmed: 8502512
Support Care Cancer. 2024 Feb 22;32(3):179
pubmed: 38383874
Am J Med Genet A. 2017 Apr;173(4):1017-1037
pubmed: 28168833
Genes (Basel). 2021 Nov 21;12(11):
pubmed: 34828445
Clin Cancer Res. 2017 Jul 1;23(13):e91-e97
pubmed: 28674117
Nat Commun. 2020 May 5;11(1):2206
pubmed: 32371905
Clin Cancer Res. 2017 Jul 1;23(13):e115-e122
pubmed: 28674120
Eur J Med Genet. 2016 Mar;59(3):116-25
pubmed: 26825391
Genet Med. 2022 Sep;24(9):1978-1985
pubmed: 35713653
Clin Cancer Res. 2017 Jun 15;23(12):e83-e90
pubmed: 28620009
Br J Cancer. 2020 Aug;123(4):619-623
pubmed: 32451468
Eur J Pediatr. 2018 Jan;177(1):53-60
pubmed: 28929227